Anybody going to listen in today? I believe it starts at 4:30 (ET).....
Investor Presentation slide 23:
2 near-term commercial opportunities in orphan lung diseases
Europe: Arikace Phase 3 trial to treat CF enrollment completed
US: Arikace Phase 2 trial to treat NTM enrollment well underway
Potential accelerated path to approval
It will be interesting to see if any information is volunteered (or asked for) regarding the anticipated initiation of the Expanded Access Program.
Is the initiation dependent upon preliminary feedback from the safety or efficacy studies?
Will the program be open to physicians Worldwide?